3782 studies found for:    Japan
Show Display Options
Rank Status Study
1 Active, not recruiting XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)
Conditions: Ischemic Heart Disease;   Angina Pectoris;   Coronary Artery Disease;   Coronary Artery Occlusion;   Myocardial Ischemia
Intervention: Device: XIENCE PRIME SV Everolimus Eluting Coronary Stent
2 Recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
3 Recruiting Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Jardiance
4 Recruiting An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Pemetrexed
5 Recruiting Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
Condition: Reflux Esophagitis
Intervention:
6 Recruiting Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
Condition: Heart Failure With Reduced Ejection Fraction (HF-rEF)
Interventions: Drug: LCZ696;   Drug: Enalapril;   Drug: Placebo to LCZ696;   Drug: Placebo to Enalapril
7 Recruiting AZD0585 Phase III Long-term Study in Japan
Condition: Hypertriglyceridemia,
Interventions: Drug: AZD0585;   Drug: AZD0585 placebo
8 Recruiting Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: S-1;   Radiation: Radiation Therapy
9 Recruiting Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
10 Recruiting A Study to Evaluate Dose-responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation
Condition: Chronic Constipation
Interventions: Drug: ASP0456;   Drug: Placebo
11 Recruiting A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: Duloxetine;   Drug: Pregabalin;   Drug: Placebo
12 Recruiting Evaluation of Dupilumab in Patients With Persistent Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668);   Drug: placebo
13 Recruiting Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (VRS-317)
Conditions: Pediatric Growth Hormone Deficiency;   Growth Disorders
Intervention: Drug: VRS-317
14 Recruiting Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women
Condition: Contraception
Intervention: Drug: Levonorgestrel (BAY98-7196)
15 Recruiting Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Avelumab;   Drug: Docetaxel
16 Recruiting A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Placebo;   Drug: Lu AA21004
17 Recruiting A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88);   Drug: non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);   Drug: sulfasalazine;   Drug: leflunomide;   Drug: bucillamine;   Drug: tacrolimus;   Drug: mizoribin
18 Recruiting A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Atezolizumab (MPDL3280A);   Drug: Carboplatin;   Drug: Nab-paclitaxel;   Drug: Paclitaxel
19 Recruiting Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Jardiance
20 Recruiting A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: MEDI4736;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Erlotinib;   Drug: MEDI4736 in combination with tremelimumab (anti-CTLA4);   Drug: tremelimumab (anti-CTLA4)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years